Premium
Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients
Author(s) -
Tak Won Young,
Park Soo Young,
Jung Min Kyu,
Jeon Seong Woo,
Cho Chang Min,
Kweon Young Oh,
Kim Sung Kook,
Choi Yong Hwan
Publication year - 2009
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2009.00515.x
Subject(s) - mitochondrial myopathy , medicine , chronic hepatitis , myopathy , virology , mitochondrial dna , hepatitis b , virus , biology , gene , biochemistry
As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.